Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1, first-in-human, multi-center study to establish safety of ADx-001 in
healthy volunteers, and safety and proof of concept in patients with confirmed amyloid
plaques in the brain (confirmed by amyloid positron emission tomography (PET)). ADx-001 is a
novel, intravenously delivered, Gd- containing molecularly targeted liposomal product that is
being developed for use in contrast-enabled MR imaging of amyloid plaques.